WillItSurvive
Medical technology and health companies · United States

Zelis

zelis.com ↗

Zelis runs claims pricing and payment tech linking 750+ health payers to providers.

Losing its protection
Assessed 22 July 2026 · Evidence as of 22 July 2026
The structural protection is eroding.
On the recordSince 22 July 2026 · Checkable from July 23, 2026 · Every call on the record Checkpoint: Discovery hearing in In re: Zelis Repricing Antitrust Litigation
The call

Zelis has the payer network and data that made it hard to replace, but its most profitable business line now sits inside a live antitrust case that could reshape the whole model.

Zelis runs a neutral middleman system that has been wired into over 750 health insurance companies for 30 years, helping them negotiate prices for out-of-network medical care. The company is hard to replace because its old system is deeply built into how insurers work and holds proprietary data about claims. However, Zelis is being sued for allegedly using its position unfairly to raise prices for hospitals and patients, and a similar lawsuit against its competitor MultiPlan could set legal rules that either kill this business model or force major changes. The outcome of the antitrust case between now and late 2026 will determine whether Zelis can keep operating as it does today or faces major restructuring.

Why
01
AI pressure: None apparent. Zelis builds its own AI for NSA dispute resolution rather than facing an outside AI disruptor; AI is a tool here, not a predator. Could AI do the core job? Unlikely.
02
Bigger players: MultiPlan/Claritev. The #1 rival in out-of-network repricing faces the same antitrust theory as Zelis, and its case ruling will likely decide both companies' fates. Could a giant copy it? Probably.
03
What protects it. Deep integrations with 750+ payers and 30 years of proprietary claims data make switching costs high and copying hard.
What would change this call
Ruling or settlement in MultiPlan/Claritev antitrust case within 6-12 months. Sets precedent for whether Zelis's own repricing model survives legal challenge.
July 23, 2026 discovery hearing outcome in In re: Zelis Repricing Antitrust Litigation. Shows whether Zelis's highest-margin OON repricing business faces structural risk.
Confirmed Zelis IPO filing with disclosed revenue mix by line. Reveals how much of revenue depends on the legally contested repricing business.
Key numbers
  • Serves 750+ payers including top 5 nationals (2026-01-12)
  • Valued at $17B in Mubadala investment (2024-12-05)
  • Processes about $80B in provider payments yearly (2024-01-26)
Named risks
  • Sherman Act antitrust suit over ERS repricing tool past motion to dismiss, in discovery since March 2026. Severity: high
  • Parallel MultiPlan/Claritev ruling could set adverse precedent for reference-based pricing model industrywide. Severity: high
  • IPO timing and valuation uncertain while litigation outcome unresolved. Severity: medium
  • Large payers could build in-house AI repricing/IDR tools, reducing reliance on third-party vendors like Zelis. Severity: medium
  • Revenue figures are unaudited private-company estimates with wide variance across sources. Severity: low
Rivals, as read in July 2026
RivalDirectionEvidence
MultiPlan/ClaritevcontestingBoth face parallel Sherman Act suits over repricing; MultiPlan case seeks >$100B damages as of 2026-07-21
Optum/UnitedHealth (Change Healthcare)contestingOptum faces payer conflict-of-interest barrier serving rival payers, limiting its ability to displace Zelis as neutral utility
WaystarcontestingPublicly traded since 2024, competes with Zelis on provider-facing billing and payments workflows
Questions people ask
Is Zelis profitable in 2026?
Zelis is private and does not disclose audited profit figures. It says it grows top and bottom line at double-digit rates and was named to the 2024 Inc. 5000 fastest-growing companies list, but no independently verified profitability figure exists as of July 2026.
Who owns Zelis?
Zelis is majority owned by private equity firms Bain Capital and Parthenon Capital since the 2019 Zelis-RedCard merger valued near $6 billion. In November 2024 a minority stake went to Mubadala, Norwest, and HarbourVest, with Bain and Parthenon retaining control.
Could AI replace Zelis?
AI is unlikely to fully replace Zelis because its core repricing and payment integrity work relies on proprietary claims data from 750+ payers built over 30 years. Zelis itself launched an AI-native NSA Claim Advantage tool on June 24, 2026, folding AI into its own workflow rather than being displaced by it.
Who is Zelis's biggest competitor?
MultiPlan (rebranded Claritev) is Zelis's closest direct competitor in out-of-network claims repricing. Both companies face parallel Sherman Act antitrust suits over algorithmic pricing, with the MultiPlan case seeking over $100 billion in pre-trebling damages as of July 21, 2026.
Is Zelis facing legal or regulatory risk?
Yes. In re: Zelis Repricing Antitrust Litigation had its motion to dismiss denied in March 2026 and moved to discovery, with a hearing scheduled July 23, 2026. Plaintiffs allege Zelis conspired with major payers to suppress out-of-network reimbursements via its ERS tool.
Will Zelis go public?
Zelis has reportedly filed confidentially for an IPO with Goldman Sachs and J.P. Morgan as lead underwriters, targeted for early 2026, though no listing had occurred as of July 2026. Valuation discussions in 2024 put the company near $15 to 17 billion.
Timeline
  • 2026-07-23Discovery hearing scheduled in In re: Zelis Repricing Antitrust Litigation
  • 2026-06-24Zelis launches AI-native NSA Claim Advantage for IDR dispute workflow
  • 2026-03Motion to dismiss denied in Zelis repricing antitrust case, discovery begins
  • 2026-01-12Zelis announces acquisition of Rivet Health for revenue cycle analytics
  • 2025-11-10Zelis partners with Duck Creek to extend ZAPP payments into P&C insurance
  • 2024-11-26Mubadala-led minority investment in Zelis closes, Bain and Parthenon retain majority
  • 2024Zelis acquires Payer Compass, adding out-of-network reimbursement pricing tools
  • 2019-10-04Zelis and RedCard complete merger, forming current Zelis entity
  • 1995Stratose founded, later becoming a root company of Zelis
Revision history
22 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
NeuralinkKingmed DiagnosticsMeinian Onehealth
More in Medical technology and health companies →
Sources